Skip to main content

IMTX

Stock
Health Care
Biotechnology

Performance overview

IMTX Price
Price Chart

Forward-looking statistics

Beta
0.65
Risk
51.38%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees362
Market cap$1.4B

Fundamentals

Enterprise value$151.3M
Revenue$169.7M
Revenue per employee
Profit margin-15.54%
Debt to equity3.43

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.20
Dividend per share
Revenue per share$1.29
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth-0.2
Credit+2.1
Liquidity-0.8
Inflation-2.1
Commodities-2.5
Interest Rates-2.2

Valuation

Dividend yield0.00%
PEG Ratio-4.33
Price to sales4.81
P/E Ratio-4.33
Enterprise Value to Revenue0.89
Price to book1.29

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (June 3, 2025)
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

On Thursday, Immatics N.V.  IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.

Benzinga (October 10, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free